Editas Medicine Inc

NASDAQ:EDIT   11:19:19 AM EDT
17.32
-0.10 (-0.57%)
Products

Editas Medicine Announces FDA Clearance Of Investigational New Drug (Ind) Application For Edit-301

Published: 12/20/2021 12:24 GMT
Editas Medicine Inc (EDIT) - Editas Medicine Announces FDA Clearance of Investigational New Drug (ind) Application for Edit-301 for the Treatment of Transfusion-dependent Beta Thalassemia.
Editas Medicine Inc - Editas Medicine Will Initiate a Phase 1/2 Clinical Trial in 2022.